Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C14H10O4 |
| Molecular Weight | 242.2273 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
c1ccc(cc1)C(=O)OOC(=O)c2ccccc2
InChI
InChIKey=OMPJBNCRMGITSC-UHFFFAOYSA-N
InChI=1S/C14H10O4/c15-13(11-7-3-1-4-8-11)17-18-14(16)12-9-5-2-6-10-12/h1-10H
| Molecular Formula | C14H10O4 |
| Molecular Weight | 242.2273 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Benzoyl peroxide (BPO) is an organic compound in the peroxide family. It consists of two benzoyl groups bridged by a peroxide link. It is one of the most important organic peroxides in terms of applications and the scale of its production. Benzoyl peroxide is used as an acne treatment, for bleaching hair and teeth. Adverse reactions are: dryness and urticarial reaction, contact dermatitis, application site burning, application site irritation and skin irritation.
Originator
Approval Year
Doses
| Dose | Population | Adverse events |
|---|---|---|
10 % 2 times / day multiple, topical Highest studied dose Dose: 10 %, 2 times / day Route: topical Route: multiple Dose: 10 %, 2 times / day Sources: |
unhealthy, 20 years n = 25 Health Status: unhealthy Condition: acne vulgaris Age Group: 20 years Sex: M+F Population Size: 25 Sources: |
Other AEs: Peeling, Erythema... Other AEs: Peeling (moderate, 55%) Sources: Erythema (moderate, 30%) |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Erythema | moderate, 30% | 10 % 2 times / day multiple, topical Highest studied dose Dose: 10 %, 2 times / day Route: topical Route: multiple Dose: 10 %, 2 times / day Sources: |
unhealthy, 20 years n = 25 Health Status: unhealthy Condition: acne vulgaris Age Group: 20 years Sex: M+F Population Size: 25 Sources: |
| Peeling | moderate, 55% | 10 % 2 times / day multiple, topical Highest studied dose Dose: 10 %, 2 times / day Route: topical Route: multiple Dose: 10 %, 2 times / day Sources: |
unhealthy, 20 years n = 25 Health Status: unhealthy Condition: acne vulgaris Age Group: 20 years Sex: M+F Population Size: 25 Sources: |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Enhancement of susceptibility to diverse skin tumor promoters by activation of the insulin-like growth factor-1 receptor in the epidermis of transgenic mice. | 1999 Jun |
|
| The combination formulation of clindamycin 1% plus benzoyl peroxide 5% versus 3 different formulations of topical clindamycin alone in the reduction of Propionibacterium acnes. An in vivo comparative study. | 2001 |
|
| Interleukin-6 expression by osteoblast-like MG63 cells challenged with four acrylic bone cements. | 2001 |
|
| Evaluation of tissue-factor production by human endothelial cells incubated with three acrylic bone cements. | 2001 Apr |
|
| A combination benzoyl peroxide and clindamycin topical gel compared with benzoyl peroxide, clindamycin phosphate, and vehicle in the treatment of acne vulgaris. | 2001 Feb |
|
| Potential role for a new combination topical therapy in treating mild to moderate acne vulgaris. | 2001 Feb |
|
| The development of antibiotic resistance in Propionibacterium acnes. | 2001 Feb |
|
| A double-blind investigation of the potential systemic absorption of isotretinoin, when combined with chemical sunscreens, following topical application to patients with widespread acne of the face and trunk. | 2001 Jan-Feb |
|
| Lipid analysis of follicular casts from cyanoacrylate strips as a new method for studying therapeutic effects of antiacne agents. | 2001 Jul |
|
| Enzyme-catalyzed decomposition of dibenzoyl peroxide in organic solvents. | 2001 Jul-Aug |
|
| [Optimized polymethyl methacrylate-embedding enables exact section examination of the femur with an uncemented femoral stem]. | 2001 Nov-Dec |
|
| The modern age of acne therapy: a review of current treatment options. | 2001 Sep-Oct |
|
| Low iron state is associated with reduced tumor promotion in a two-stage mouse skin carcinogenesis model. | 2002 Aug |
|
| Umbilical cord care: the effect of eight different cord-care regimens on cord separation time and other outcomes. | 2002 Jan |
|
| A randomized, double-blind comparison of a clindamycin phosphate/benzoyl peroxide gel formulation and a matching clindamycin gel with respect to microbiologic activity and clinical efficacy in the topical treatment of acne vulgaris. | 2002 Jul |
|
| Oral toxicity of topical preparations. | 2002 Mar |
|
| Preliminary results of a nonrandomized, multicenter, open-label study of patient satisfaction after treatment with combination benzoyl peroxide/clindamycin topical gel for mild to moderate acne. | 2002 Oct |
|
| Inhibition of benzoyl peroxide and ultraviolet-B radiation induced oxidative stress and tumor promotion markers by cycloartenol in murine skin. | 2003 |
|
| Determination of organic peroxides by liquid chromatography with on-line post-column ultraviolet irradiation and peroxyoxalate chemiluminescence detection. | 2003 Feb 14 |
|
| A randomized, double-blind, multicenter, parallel group study to compare relative efficacies of the topical gels 3% erythromycin/5% benzoyl peroxide and 0.025% tretinoin/erythromycin 4% in the treatment of moderate acne vulgaris of the face. | 2003 Jan-Feb |
|
| Functionalization of carbon nanotubes by free radicals. | 2003 May 1 |
|
| Improved one-pot synthesis of styryl tetrahydrofurans and cyclohexanes by radical addition to beta-nitrostyrenes in the presence of benzoyl peroxide. | 2003 May 9 |
Patents
Sample Use Guides
In Vivo Use Guide
Curator's Comment:: Benzamicin gel in combination with adapalene (instead of erythromycin) have to be applied once daily after washing.
Benzamicin gel should be applied twice daily.
Route of Administration:
Topical
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Jun 26 06:33:29 UTC 2021
by
admin
on
Sat Jun 26 06:33:29 UTC 2021
|
| Record UNII |
W9WZN9A0GM
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
JECFA EVALUATION |
E-928
Created by
admin on Sat Jun 26 06:33:29 UTC 2021 , Edited by admin on Sat Jun 26 06:33:29 UTC 2021
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
13.4
Created by
admin on Sat Jun 26 06:33:29 UTC 2021 , Edited by admin on Sat Jun 26 06:33:29 UTC 2021
|
||
|
CODEX ALIMENTARIUS (GSFA) |
E-928
Created by
admin on Sat Jun 26 06:33:29 UTC 2021 , Edited by admin on Sat Jun 26 06:33:29 UTC 2021
|
||
|
CFR |
21 CFR 176.170
Created by
admin on Sat Jun 26 06:33:29 UTC 2021 , Edited by admin on Sat Jun 26 06:33:29 UTC 2021
|
||
|
NCI_THESAURUS |
C28394
Created by
admin on Sat Jun 26 06:33:29 UTC 2021 , Edited by admin on Sat Jun 26 06:33:29 UTC 2021
|
||
|
WHO-ATC |
D10AE01
Created by
admin on Sat Jun 26 06:33:29 UTC 2021 , Edited by admin on Sat Jun 26 06:33:29 UTC 2021
|
||
|
CFR |
21 CFR 333.310
Created by
admin on Sat Jun 26 06:33:29 UTC 2021 , Edited by admin on Sat Jun 26 06:33:29 UTC 2021
|
||
|
EPA PESTICIDE CODE |
128964
Created by
admin on Sat Jun 26 06:33:29 UTC 2021 , Edited by admin on Sat Jun 26 06:33:29 UTC 2021
|
||
|
CFR |
21 CFR 184.1157
Created by
admin on Sat Jun 26 06:33:29 UTC 2021 , Edited by admin on Sat Jun 26 06:33:29 UTC 2021
|
||
|
WHO-VATC |
QD10AE01
Created by
admin on Sat Jun 26 06:33:29 UTC 2021 , Edited by admin on Sat Jun 26 06:33:29 UTC 2021
|
||
|
WHO-ATC |
D10AE51
Created by
admin on Sat Jun 26 06:33:29 UTC 2021 , Edited by admin on Sat Jun 26 06:33:29 UTC 2021
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
SUB122302
Created by
admin on Sat Jun 26 06:33:29 UTC 2021 , Edited by admin on Sat Jun 26 06:33:29 UTC 2021
|
PRIMARY | |||
|
M2389
Created by
admin on Sat Jun 26 06:33:29 UTC 2021 , Edited by admin on Sat Jun 26 06:33:29 UTC 2021
|
PRIMARY | Merck Index | ||
|
C47411
Created by
admin on Sat Jun 26 06:33:29 UTC 2021 , Edited by admin on Sat Jun 26 06:33:29 UTC 2021
|
PRIMARY | |||
|
Benzoyl Peroxide
Created by
admin on Sat Jun 26 06:33:29 UTC 2021 , Edited by admin on Sat Jun 26 06:33:29 UTC 2021
|
PRIMARY | |||
|
BENZOYL PEROXIDE
Created by
admin on Sat Jun 26 06:33:29 UTC 2021 , Edited by admin on Sat Jun 26 06:33:29 UTC 2021
|
PRIMARY | |||
|
E-928
Created by
admin on Sat Jun 26 06:33:29 UTC 2021 , Edited by admin on Sat Jun 26 06:33:29 UTC 2021
|
PRIMARY | |||
|
CHEMBL1200370
Created by
admin on Sat Jun 26 06:33:29 UTC 2021 , Edited by admin on Sat Jun 26 06:33:29 UTC 2021
|
PRIMARY | |||
|
372
Created by
admin on Sat Jun 26 06:33:29 UTC 2021 , Edited by admin on Sat Jun 26 06:33:29 UTC 2021
|
PRIMARY | |||
|
BENZOYL PEROXIDE
Created by
admin on Sat Jun 26 06:33:29 UTC 2021 , Edited by admin on Sat Jun 26 06:33:29 UTC 2021
|
PRIMARY | Description: A white, amorphous or granular powder. Solubility: Practically insoluble in water; soluble in acetone R; soluble in dichloromethane R with separation of water; slightlysoluble in ethanol (~750 g/l) TS. Category: Keratolytic agent. Storage: Hydrous Benzoyl peroxide should be kept in a container that has been treated to reduce static discharge and that has a device for the release of excess pressure. Store at a temperature between 2 and 8 ?C, protected from light. Additional information: CAUTION: Hydrous Benzoyl peroxide may explode at temperatures higher than 60 ?C or if its water content is too low. It may burst into flame in the presence of reducing substances. Unused material must not be returned to the original container but destroyed by treating with sodium hydroxide (~80 g/l) TS to a point where no iodine is liberated after acidifying with hydrochloric acid (~70 g/l) TS and adding a crystal of potassium iodide R. Hydrous Benzoyl peroxide loses water rapidly on exposure to air. It must be handled with care, avoiding contact with the skin and mucous membranes and inhalation of airborne particles. | ||
|
202-327-6
Created by
admin on Sat Jun 26 06:33:29 UTC 2021 , Edited by admin on Sat Jun 26 06:33:29 UTC 2021
|
PRIMARY | |||
|
7187
Created by
admin on Sat Jun 26 06:33:29 UTC 2021 , Edited by admin on Sat Jun 26 06:33:29 UTC 2021
|
PRIMARY | |||
|
328
Created by
admin on Sat Jun 26 06:33:29 UTC 2021 , Edited by admin on Sat Jun 26 06:33:29 UTC 2021
|
PRIMARY | |||
|
W9WZN9A0GM
Created by
admin on Sat Jun 26 06:33:29 UTC 2021 , Edited by admin on Sat Jun 26 06:33:29 UTC 2021
|
PRIMARY | |||
|
DUAC
Created by
admin on Sat Jun 26 06:33:29 UTC 2021 , Edited by admin on Sat Jun 26 06:33:29 UTC 2021
|
PRIMARY | APPROVED MARCH 2015 | ||
|
SUB11742MIG
Created by
admin on Sat Jun 26 06:33:29 UTC 2021 , Edited by admin on Sat Jun 26 06:33:29 UTC 2021
|
PRIMARY | |||
|
D001585
Created by
admin on Sat Jun 26 06:33:29 UTC 2021 , Edited by admin on Sat Jun 26 06:33:29 UTC 2021
|
PRIMARY | |||
|
SUB13020MIG
Created by
admin on Sat Jun 26 06:33:29 UTC 2021 , Edited by admin on Sat Jun 26 06:33:29 UTC 2021
|
PRIMARY | |||
|
DB09096
Created by
admin on Sat Jun 26 06:33:29 UTC 2021 , Edited by admin on Sat Jun 26 06:33:29 UTC 2021
|
PRIMARY | |||
|
94-36-0
Created by
admin on Sat Jun 26 06:33:29 UTC 2021 , Edited by admin on Sat Jun 26 06:33:29 UTC 2021
|
PRIMARY | |||
|
1418
Created by
admin on Sat Jun 26 06:33:29 UTC 2021 , Edited by admin on Sat Jun 26 06:33:29 UTC 2021
|
PRIMARY | RxNorm | ||
|
94-36-0
Created by
admin on Sat Jun 26 06:33:29 UTC 2021 , Edited by admin on Sat Jun 26 06:33:29 UTC 2021
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
IMPURITY -> PARENT |
|
||
|
|
IMPURITY -> PARENT |
|
||
|
|
IMPURITY -> PARENT |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
